NAVXPRESS Trademark

Trademark Overview

On Tuesday, May 31, 2022, a trademark application was filed for NAVXPRESS with the United States Patent and Trademark Office. The USPTO has given the NAVXPRESS trademark a serial number of 97436697. The federal status of this trademark filing is REGISTERED as of Tuesday, November 12, 2024. This trademark is owned by REGENXBIO Inc.. The NAVXPRESS trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of reagents for scientific and medical research and development; Custom manufacturing services, namely, production for others of clinical and medical reagents for use in gene therapy, for development of pharmaceutical preparations for use in gene therapy, and of therapeutic compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy, including gene therapy delivery of antibody biologics, enzymes and RNA interference (RNAi)

Custom design and development of reagents for scientific and medical research and development
navxpress

General Information

Serial Number97436697
Word MarkNAVXPRESS
Filing DateTuesday, May 31, 2022
Status700 - REGISTERED
Status DateTuesday, November 12, 2024
Registration Number7566017
Registration DateTuesday, November 12, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 14, 2023

Trademark Statements

Goods and ServicesCustom manufacture of reagents for scientific and medical research and development; Custom manufacturing services, namely, production for others of clinical and medical reagents for use in gene therapy, for development of pharmaceutical preparations for use in gene therapy, and of therapeutic compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy, including gene therapy delivery of antibody biologics, enzymes and RNA interference (RNAi)
Goods and ServicesCustom design and development of reagents for scientific and medical research and development

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, February 6, 2023
Primary Code040
First Use Anywhere DateThursday, June 9, 2022
First Use In Commerce DateTuesday, March 14, 2023
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 8, 2022
Primary Code042
First Use Anywhere DateThursday, June 9, 2022
First Use In Commerce DateTuesday, March 14, 2023

Trademark Owner History

Party NameREGENXBIO Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850
Party NameREGENXBIO Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20850
Party NameREGENXBIO Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events

Event DateEvent Description
Friday, June 3, 2022NEW APPLICATION ENTERED
Wednesday, June 8, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 25, 2022ASSIGNED TO EXAMINER
Tuesday, September 6, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 25, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 25, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 25, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 6, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, February 6, 2023EXAMINERS AMENDMENT E-MAILED
Monday, February 6, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, February 6, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, February 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 14, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 9, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, June 17, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 17, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, June 17, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 17, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 17, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, June 17, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 17, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 17, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, June 17, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 21, 2023USE AMENDMENT FILED
Monday, August 21, 2023TEAS STATEMENT OF USE RECEIVED
Saturday, August 26, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, August 26, 2023STATEMENT OF USE PROCESSING COMPLETE
Friday, September 29, 2023SU - NON-FINAL ACTION - WRITTEN
Friday, September 29, 2023NON-FINAL ACTION E-MAILED
Friday, September 29, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 28, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, December 28, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, March 28, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 29, 2024ASSIGNED TO LIE
Tuesday, October 8, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, October 8, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, November 12, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, November 12, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, December 12, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 12, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, December 12, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Related Keywords

navxpress gene development therapy medical custom reagents therapeutic research biologics scientific